BEAM base editing platform reports robust efficacy and safety data
BEAM says its base editing platform delivers precise, durable genetic corrections and points to new efficacy and safety data in alpha-1 antitrypsin deficiency. Pivotal trials are progressing with regulatory alignment and commercial preparations underway.
Base editing platform enables precise, durable genetic corrections for multiple diseases, with new data showing robust efficacy and safety in alpha-1 antitrypsin deficiency. Pivotal trials are progressing, regulatory alignment is strong, and commercial preparations for sickle cell and other program…